Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
JNJ News
These two market leaders have increased their dividends for a combined 115 years. It's impossible to predict with certainty whether a recession is coming, but...
(RTTNews) - Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $966 million to the family of a California woman who died from a rare and aggressiv...
Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $74 from $62 and keeps a Buy rating on the shares. The price target hike follo...
Analyst ratings
52%
of 25 ratingsMore JNJ News
Johnson & Johnson was told by a California jury to pay $966 million to the family of a deceased woman who blamed her cancer on life-long use of the company’s ba...
In the past week, U.S. Orthopaedic Partners announced a new agreement selecting Johnson & Johnson as its official vendor for total joint products, giving the ph...
A jury in Los Angeles Superior Court awarded a $966M verdict against Johnson & Johnson to the children of a woman who died of mesothelioma in what was the highe...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
(RTTNews) - Johnson & Johnson (JNJ) on Tuesday announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra in adults with moderately t...
Johnson & Johnson announced new data on the Acuvue Oasys Max 1-Day for Astigmatism contact lenses which showed higher end-of-day comfort as compared to Dailies...
Johnson & Johnson announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA subcutaneous induction and maintenance therapy in adults with moder...